Daniel Spratt, MD

About

Dan Spratt, MD, is a board-certified, international expert in the management of prostate cancer. Dr. Spratt attended Vanderbilt University (Nashville, Tennessee) for his medical training and completed his Radiation Oncology residency at Memorial Sloan Kettering (New York, New York). He joined the University of Michigan in 2015, where he developed a large NIH-funded translational and clinical research group.

While at the University of Michigan, Dr. Spratt also served as the Associate Chair for Clinical Research, the co-Chair for Genitourinary Clinical Trials for the Rogel Cancer Center, and the founding co-Director of the Spine Oncology Program. In addition, Dr. Spratt held leadership roles in the NIH Prostate SPORE and the U10 LAPS grant for cooperative group trials. Dr. Spratt received a number of awards in recognition for his teaching, mentorship, research and service during his time at University of Michigan. Furthermore, he was promoted to a tenured full professor faster than any other faculty member at the university, obtaining tenure in just five years following the completion of his training at Memorial Sloan Kettering.

Dr. Spratt currently serves as chair of the Department of Radiation Oncology at University Hospitals Cleveland Medical Center, and he joined the faculty of Case Western Reserve University School of Medicine in 2021. He also holds the Vincent K. Smith Chair in Radiation Oncology. Dr. Spratt’s clinical expertise encompasses the management of genitourinary cancers (prostate, bladder, kidney, and testicular), metastasis-directed radiotherapy, and spine stereotactic body radiotherapy. Patients travel from all over the world to seek his expert care for these conditions.

Dr. Spratt’s research expertise centers on the development and validation of prognostic and predictive biomarkers used to personalize treatment of cancer patients while avoiding over- and under-treatment. He has published over 300 peer-reviewed manuscripts, including practice-changing work in the New England Journal of Medicine, JAMA, Lancet Oncology, JAMA Oncology and the Journal of Clinical Oncology. Dr. Spratt has received federal funding from the NIH, Department of Defense, and numerous foundations for his research. He is the principal or co-principal investigator on over 10 institutional, national or multi-national clinical trials.

Dr. Spratt serves as the Intact Prostate Cancer Lead for the NRG Oncology Genitourinary Subcommittee and is a member of the National Cancer Institute’s Genitourinary Steering Committee. Presently, he is also the Senior Editor for radiation oncology’s primary biomedical journal, the International Journal of Radiation Biology and Physics. In addition, he serves on study sections for the NIH, Department of Defense, Prostate Cancer Canada, Prostate Cancer United Kingdom, and multiple other national foundations, while also serving as a reviewer for over 25 journals. Dr. Spratt has mentored over 30 undergraduates, graduate students, medical students, residents, fellows and junior faculty. He regularly receives invitations from all over the world to give lectures on the management and personalization of prostate cancer.

Dr. Spratt’s primary professional goal is to create a world-class Department of Radiation Oncology that provides cutting edge personalized and compassionate care.

Awards

2014 – ASTRO’s 56th Annual Basic Science Abstract Award in the Biology
2016 – Association of Residents in Radiation Oncology (ARRO) Teacher of the Year Award
2017 – Annual Clinical Faculty Teacher of the Year Award
2018 – Dean’s Award for Clinical Research
2018 – ASTRO’s Steven Liebel Award
2019 – Graduate Medical Education’s Teacher/Mentor of the Year Award
2019 – Cancer Clinical Investigator Team Leadership Award (CCITLA) National Institutes of Health Award
2020 – Outstanding Clinical Research Award, Rogel Cancer Center